Drug
Obatoclax clinical trials
Also written GX15-070MS.
- studies test it
- 18
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
18 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 13
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 7
Gemin X (11) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Bortezomib (3) · Rituximab (2) · Docetaxel (1) · Topotecan (1) · Temozolomide (1) · Dexrazoxane (1) · Doxorubicin (1) · Fludarabine phosphate (1)
Studies
Open first, then newest update. How each study uses obatoclax is read from its arms, and is right about nine times in ten.
Testing it · 18
- Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)CompletedPhase 2Gemin XNCT00427856Written as Obatoclax mesylate
- A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic MelanomaTerminatedPhase 1/2Gemin XNCT00724841Written as Obatoclax Mesylate
- A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)CompletedPhase 1/2Gemin XNCT00682981Written as Obatoclax
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedPhase 1/2Gemin XNCT00407303Written as Obatoclax mesylate
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung CancerCompletedPhase 1/2Gemin XNCT00405951Written as Obatoclax mesylate 250 ml
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedPhase 1National Cancer Institute (NCI)NCT00538187Written as obatoclax mesylate
- Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid TumorsCompletedPhase 1/2National Cancer Institute (NCI)NCT00521144Written as obatoclax mesylate
- Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00719901Written as obatoclax mesylate
- A Phase I/II Study of GX15-070MS in Untreated CLLCompletedPhase 1Gemin XNCT00600964Written as GX15-070MS
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological MalignanciesCompletedPhase 1Gemin XNCT00438178Written as Obatoclax mesylate (GX15-070MS)
- Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedPhase 1National Cancer Institute (NCI)NCT00933985Written as obatoclax mesylate
- Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 1National Cancer Institute (NCI)NCT00612612Written as obatoclax mesylate
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid MetaplasiaCompletedPhase 2Gemin XNCT00360035Written as Obatoclax mesylate (GX15-070MS)
- Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)CompletedPhase 2Gemin XNCT00684918Written as Obatoclax
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)CompletedPhase 2Gemin XNCT00413114Written as Obatoclax mesylate (GX15-070MS)
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnPhase 1/2National Cancer Institute (NCI)NCT01238146Written as obatoclax mesylate
- Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's LymphomaCompletedPhase 2Gemin XNCT00359892Written as Obatoclax mesylate (GX15-070MS)
- Obatoclax for Systemic MastocytosisTerminatedPhase 2M.D. Anderson Cancer CenterNCT00918931Written as Obatoclax Mesylate
Codes
What other systems call obatoclax · ClinicalTrials.gg INT005113
- MeSH (NLM) C520962obatoclaxConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QN4128B52AOBATOCLAXConfirmed FDA, NLM
- NCI Thesaurus C60770ObatoclaxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520962 | obatoclax | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QN4128B52A | OBATOCLAX | Confirmed FDA, NLM |
| NCI Thesaurus | C60770 | Obatoclax | One source FDA |
Also registered as obatoclax mesylate (UNII 39200FJ43J).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.